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Background:  The  development  of  abuse  deterrent  formulations  is one  strategy  for reducing  prescrip-
tion  opioid  misuse  and  abuse.  A putative  abuse  deterrent  formulation  of oxycodone  extended  release
(OxyContin®) was  introduced  in 2010.  Early  reports  demonstrated  reduced  abuse  and  diversion,  how-
ever, an  analysis  of  social  media  found  32  feasible  methods  to circumvent  the  abuse  deterrent  mechanism.
We  measured  trends  of  diversion,  abuse  and  street  price  of  OxyContin  to assess  the  durability  of the initial
reduction  in  abuse.
Methods: Data  from  the  Poison  Center  Program,  Drug  Diversion  Program,  Opioid  Treatment  Program,
Survey  of  Key  Informant  Patients  Program  and  StreetRx  program  of the  Researched  Abuse, Diversion,  and
Addiction-Related  Surveillance  (RADARS®) System  were  used.  The  average  quarterly  rates  of  abuse  and
diversion  for  OxyContin  were  compared  from  before  reformulation  to the  rate  in  second  quarter  2015.
Rates  were  adjusted  for population  using US  Census  data  and  drug  availability.
Results:  OxyContin  abuse  and  diversion  declined  signiﬁcantly  each  quarter  after  reformulation  and  per-
sisted for  5 years.  The  rate  of abuse  of  other  opioid  analgesics  increased  initially  and  then  decreased,
but  to lesser  extent  than  OxyContin.  Abuse  through  both  oral  and  non-oral  routes  of  self-administration
declined  following  the reformulation.  The  geometric  mean  difference  in  the  street  price  of reformulated
OxyContin  was 36%  lower  than  the reformulated  product  in the  year  after  reformulation.
Discussion:  Despite  methods  to circumvent  the  abuse  deterrent  mechanism,  abuse  and  diversion  of Oxy-
Contin  decreased  promptly  following  the  introduction  of a crush-  and  solubility-  resistant  formulation
e  ove
rs.  Puand  continued  to  decreas
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. IntroductionMisuse and abuse of prescription analgesics is a major health
roblem. In 2014, there were 2.2 million current nonmedical
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users of prescription pain relievers in the United States (Center
for Behavioral Health Statistics and Quality, 2015). More than
16,000 deaths were attributed to prescription pain relievers in 2013
(Hedegaard et al., 2015). In 2011, the Ofﬁce of National Drug Con-
trol Policy issued a national strategy to combat prescription drug
abuse (United States Ofﬁce of National Drug Control Policy, 2011).
The strategy included several components, including research into
formulations with abuse deterrent properties. In 2015, the FDA
released guidance regarding the development of abuse deterrent
formulations (United States Food and Drug Administration, 2015).
One speciﬁed property was physical-chemical barriers, which
involves making a tablet difﬁcult to crush; thereby inhibiting use
through chewing, nasal insufﬂation, injection, or smoking.
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
2 cohol D
c
F
i
f
ﬁ
d
a
d
2
u
S
a
2
r
e
t
h
o
a
s
o
t
r
m
2
2
S
l
m
o
p
a
a
o
s
n
d
i
r
a
d
e
P
q
m
a
u
s
2
e
I
t
t
c20 S.G. Severtson et al. / Drug and Al
OxyContin® is an extended release (ER) formulation of oxy-
odone that became a popular drug of abuse (United States
ood and Drug Administration, 2001). In 2010, the manufacturer
ntroduced a reformulated tablet that was difﬁcult to crush and
ormed a viscous hydrogel to make snorting and injection dif-
cult (Alexander et al., 2014). The FDA approved new labeling
escribing the abuse deterrent features and subsequently denied
pplications from other oxycodone ER formulations without abuse
eterrent features (United States Food and Drug Administration,
013). Reformulated OxyContin and its authorized generic prod-
cts remain the only form of oxycodone ER marketed in the United
tates.
Initial reports suggested that reformulation reduced the abuse
nd diversion of OxyContin (Severtson et al., 2013; Butler et al.,
013). However, a review of internet forums found 32 feasible
ecipes to overcome the tamper resistant properties (McNaughton
t al., 2014). Previous research suggests that many abusers switch
o other products, particularly immediate release oxycodone and
ydromorphone (Cicero et al., 2012; Havens et al., 2014). If meth-
ds to circumvent abuse deterrent methods became widespread,
buse and diversion could return to high rates. OxyContin repre-
ents a sentinel opportunity to assess the durability of the strategy
f physical-chemical abuse deterrent properties.
We analyzed rates of opioid analgesic abuse and diversion for
he 5 years following reformulation to determine whether initial
eductions in OxyContin abuse persisted despite the availability of
ethods to circumvent the abuse deterrent properties.
. Methods
.1. Data sources
The Researched, Abuse, Diversion, and Addiction Related
urveillance (RADARS®) System provides post-marketing surveil-
ance of prescription medication abuse and diversion to phar-
aceutical companies, regulatory agencies, and policy making
rganizations. The System is comprised of multiple surveillance
rograms that independently gather data on prescription drug
buse from different perspectives. The RADARS System is owned
nd operated by the Denver Health and Hospital Authority, which
perates the public hospital for the city and county of Denver. The
ystem is supported by subscriptions from pharmaceutical compa-
ies that produce prescription opioids or stimulants, which use the
ata for risk management and postmarketing surveillance report-
ng to the Food and Drug Administration.
The Poison Center Program studies acute health events by
ecording the substances involved in poison center cases classiﬁed
s intentional abuse. The Drug Diversion Program measures drug
iversion by recording the drugs involved in cases opened by law
nforcement drug diversion investigators. The Opioid Treatment
rogram and the Survey of Key Informants’ Patients Program both
uery new patients entering substance-abuse treatment about
edications that they have abused. The StreetRx Program utilizes
 crowdsourcing website that gathers street price data for drugs
sing a publically-accessible website. Further information on each
urveillance program has been published (Dart et al., 2015).
.2. Deﬁnitions
In the Poison Center Program, a case involves an individual
xposure contact in which the case was coded to the category of
ntentional Abuse, which is deﬁned as an exposure resulting from
he intentional improper or incorrect use of a substance where
he victim was likely attempting to gain a euphoric or other psy-
hotropic effect (American Association of Poison Control Centers,ependence 168 (2016) 219–229
2014). Poison Center Program mentions are the total number of
active pharmaceutical ingredient (API) reports involved for all cases
within a deﬁned group. Mentions differ from cases in that an indi-
vidual (case) may  be exposed to more than one product (mention).
There is an average of 1.04 opioid mentions per case.
In the Opioid Treatment and Survey of Key Informants’ Patients
programs, a case is deﬁned as a survey respondent endorsing the
abuse of a prescription opioid in the preceding 30 days. In these
programs, mentions are the total number of endorsements. The
average number of mentions per case is 1.68 for the Opioid Treat-
ment Program and 1.83 for the Survey of Key Informant Patients
Program.
In the Drug Diversion Program, a case is deﬁned as an investiga-
tion, which can have one or more mentions (drugs involved in the
case). Drug diversion ofﬁcers submit data quarterly on the number
of new cases involving prescription products within their jurisdic-
tion. These cases arise from arrests, street buys and sales by law
enforcement agents, and investigation of prescribers, among other
reasons.
In StreetRx, users enter the price of drugs they paid or heard
was paid from an extensive list of drugs provided on the website
(http://streetrx.com). StreetRx submissions from the United States
for OxyContin that included a price paid, dosage strength, and date
were included.
Quarterly population rates were calculated by dividing the total
number of cases by the sum of the population in the 3-digit ZIP
codes covered by each program using 2010 US census results, thus
allowing for each individual to contribute once to the numerator
and once to the denominator within each drug group. In con-
trast, rates adjusted for prescriptions dispensed are calculated by
dividing the sum of the mentions by the sum of the projected pre-
scription volume in the 3-digit ZIP codes covered by each program.
For mention based rates, such as prescription rates, a single indi-
vidual may  be counted multiple times in both the numerator and
denominator. Quarterly prescription rates were calculated using
the projected number of prescriptions dispensed as provided using
a proprietary method by IMS  Government Solutions, Inc., a sub-
sidiary of IMS  Health, Inc. (Danbury, CT) for each drug. Due to
preferences indicated by US FDA, we  also calculated rates using the
concept of “extended dosage units,” which is deﬁned as individual
tablets or capsules dispensed at retail pharmacies (IMS Govern-
ment Solutions, Danbury CT; Secora et al., 2014)
2.3. Analysis procedures
Generalized linear modeling was  used to compare the differ-
ence in mean population intentional abuse and diversion rates in
the year prior to the reformulation (Baseline period: July 2009
through June 2010) to the estimated rate for 2015 quarter (2Q,
April 2015 through June 2015) based upon the trend (slope) of
the post-reformulation rates. Changes in the OxyContin rate were
compared to changes for the Other Opioid group (oral dosage
forms of opioid analgesics: hydrocodone, hydromorphone, mor-
phine, oxymorphone, tramadol, tapentadol, and immediate release
oxycodone). The group was  chosen because published evidence
indicates that abusers switch to a variety of other prescription
opioid analgesics, therefore, we  combined the oral dosage unit for-
mulation of those products into a single comparison group (Cicero
et al., 2012; Havens et al., 2014). Oxymorphone data were only
available from 2011 in the Drug Diversion program and from 2011
Q3 in the Opioid Treatment and Survey of Key Informants’ Patients
Programs. A Poisson regression analysis was  used to calculate the
expected rates and 95% conﬁdence bands for each time period
and drug group. A drug group speciﬁc dispersion parameter was
included in the model to allow for unequal variances and overdis-
persion. The six month period encompassing the introduction of
S.G. Severtson et al. / Drug and Alcohol D
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reformulated OxyContin was  considered a transition period and
excluded from the analysis. Therefore, quarterly rates from July,
2009 to June, 2010 (before reformulation) and rates from January,
2011 to June, 2015 (after reformulation) were used in all analyses.
The route of administration for poison center cases was com-
pared before and after introduction of reformulated OxyContin
using generalized linear modeling. Comparisons were conducted
by route of administration and by time period. Oral routes (swal-
lowing tablet whole, dissolving in mouth, and chewing then
swallowing) were compared to non-oral routes (injection or
inhalation, which is primarily insufﬂation). A speciﬁc dispersion
parameter for route of OxyContin administration was included
in the model. Product speciﬁc route information was  collected
beginning in January, 2010; therefore the analysis period includes
quarterly rates from January, 2010 to June, 2010 (before reformu-
lation) and January, 2011 to June, 2015 (after reformulation).
Street price data were normalized by the milligram strength of
the unit purchased, providing price per milligram as the analysis
metric. The price data from the StreetRx Program were positively
skewed, therefore, in multivariate models the price data were
log-transformed and regressed on a covariate for year and formu-
lation. This calculation provides a difference in the geometric mean
price adjusted for time. Geometric means were used because they
approximate the median and are considered more representative
than arithmetic means in economic research.
3. Results
3.1. Number of prescriptions dispensed
Prescriptions dispensed for OxyContin decreased from
1,608,747 in second quarter 2010 (2010-Q2) to 1,211,593 in
2015-Q2, a 25% reduction (Fig. 1). In contrast, the Other Opioid
group increased 7% from 50,814,374 to 54,567,288 during the
same period. Except for hydrocodone combination formulations
and OxyContin, prescriptions dispensed increased for each opioid
analgesic.
The decrease in prescriptions was  biphasic. In the 6 month
period of 2010-Q3 through 201-Q1, OxyContin prescriptions dis-
pensed declined 13.9%, while prescriptions for Other Opioids
increased 5.9%. Subsequently, for the period from 2011-Q2 through
2015-Q2, OxyContin declined 12.9% and Other Opioids declined
5.9%.
3.2. Poison center program intentional abuse
A total of 2159 OxyContin cases and 19,815 Other Opioid cases
were received during the study period. The population adjusted
rate for OxyContin decreased −75.0% (95% CI: −78.4, −71.1) after
reformulation (Table 1, Fig. 2A), from baseline to 2015-Q2. This was
the greatest decrease among the opioids and signiﬁcantly larger
than the Other Opioid group (-32.8%, 95% CI: −37.4, −27.9). The rate
for OxyContin declined −6.1% (95% CI: −7.1% to −5.1%) each quarter
on average following reformulation, which was greater than the
Other Opioid group) (−3.1%, 95% CI: −3.5, −2.6).
The prescription adjusted OxyContin rate decreased −62.3%
(95% CI: −67.9, −55.6) following reformulation (Table 1, Fig. 2B)
from baseline to 2015-Q2, which was  the greatest among the opioid
categories and signiﬁcantly greater than the Other Opioid group (-
33.7%, 95% CI: −38.1, −29.0). OxyContin rates declined −5.0% (95%
CI: −6.1%, −3.8) per quarter on average following reformulation,
which was signiﬁcantly greater than the Other Opioid group (−2.6%,
95% CI: −3.0, −2.2).
222 S.G. Severtson et al. / Drug and Alcohol Dependence 168 (2016) 219–229
Fig. 1. Number of opioid analgesic prescriptions dispensed in the United States, April 1, 2009 to June 30, 2015. The Other Opioid Group is comprised of immediate release
(IR)  oxycodone, IR and extended release (ER) hydrocodone, IR and ER morphine, IR and ER hydromorphone, IR and ER tramadol, IR and ER oxymorphone, and IR and ER
tapentadol. The period of time indicated by shading was excluded from statistical analysis.
Source: IMS Government Solutions, Inc., a subsidiary of IMS  Health, Inc., Danbury, CT.
Fig. 2. Relative change in rate of Intentional Abuse cases, Poison Center Program, 2009–2015. The Other Opioid Group is comprised of immediate release (IR) oxycodone, IR
and  extended release (ER) hydrocodone, IR and ER morphine, IR and ER hydromorphone, IR and ER tramadol, IR and ER oxymorphone, and IR and ER tapentadol. The period
of  time indicated by shading was  excluded from statistical analysis. CI − 95% Conﬁdence intervals. (A) Rate adjusted for population. (B) Rate adjusted for prescription volume.
cohol D
−
g
3
w
r
r
o
g
−
w
−
(
d
g
−
q
t
(
t
−
3
c
d
b
o
O
d
l
g
(
(
a
C
p
g
−
d
l
3
o
d
b
t
g
−
s
−
(
Q
O
iS.G. Severtson et al. / Drug and Al
The units-dispensed OxyContin rate decreased −56.1% (95% CI:
62.7, −48.3) following reformulation, which was signiﬁcantly
reater than the Other Opioid group (−34.4%, 95% CI −39.6, −28.8).
.3. Drug diversion program
A total of 4142 OxyContin cases and 57,135 Other Opioid cases
ere received during the study period. The population adjusted
ate for OxyContin decreased −89.4% (95% CI: −92.4, −85.2) after
eformulation (Table 1, Fig. 3A). The decrease was  greatest of the
pioid categories and statistically different than the Other Opioid
roup (−26.8%, 95% CI: −36.0, −16.3). OxyContin rates declined
8.9% (95% CI: −11.2, −6.5) each quarter following reformulation,
hich was greater than the Other Opioid group (−2.8%, 95% CI:
3.7, −1.9).
The prescription adjusted OxyContin rate decreased −85.8%
95% CI: −89.7, −80.5) after reformulation (Table 1, Fig. 3B). The
ecrease was greatest of the opioid categories and statistically
reater than the Other Opioid group (−31.7%, 95% CI: −40.3%,
21.8). OxyContin rates declined −8.3% (95% CI: −10.6, −6.1) per
uarter after reformulation, which was signiﬁcantly greater than
he Other Opioid group (−3.6%, 95% CI: −3.6, −1.8).
The dosage unit adjusted rate for OxyContin decreased −83.4%
95% CI: −88.0%, −76.0%) following reformulation, which was  sta-
istically greater than the Other Opioid group (−33.2%, 95% CI −42.1,
23.0).
.4. Opioid treatment program
A total of 8176 OxyContin cases and 15,873 Other Opioid
ases were received. The population adjusted rate for OxyContin
ecreased −82.6% (95% CI: −86.7, −77.1) after reformulation from
aseline to 2015-Q2 (Table 1, Fig. 4A). The decrease was  greatest
f the opioid categories and statistically greater than the Other
pioid group (−32.0%, 95% CI: −40.1, −22.9). The OxyContin rate
eclined −9.4% (95% CI: −11.1, −7.6) each quarter on average fol-
owing reformulation, which was greater than the Other Opioid
roup (−3.5%, 95% CI: −4.3, −2.7).
The prescription adjusted OxyContin rate decreased −72.8%
95% CI: −80.6, −62.0) after reformulation from baseline to 2015-Q2
Table 1, Fig. 4B). The decrease was greatest of the opioid categories
nd statistically greater than the Other Opioid group (−30.9%, 95%
I: −40.4, −19.8). OxyContin declined −8.2% (95% CI: −10.4, −6.0)
er quarter on average, which was greater than the Other Opioid
roup (−3.2%, 95% CI: −4.2 to −2.3).
The units dispensed OxyContin rate decreased −68.4% (95% CI:
77.5%, −55.7) following reformulation, which was  signiﬁcantly
ifferent than the Other Opioid group (−31.2%, 95% CI −41.4, −19.3)
ower than before the reformulation.
.5. Survey of key informants’ patients program
A total of 3987 OxyContin cases OxyContin and 8451 Other Opi-
id cases were received. The population adjusted rate for OxyContin
ecreased −53.9% (95% CI: −64.1, −40.7) after reformulation from
aseline to 2015-Q2 (Table 1, Fig. 5A). The decrease was greatest of
he opioid categories and statistically greater than the Other Opioid
roup −7.2% (95% CI: −19.4, 6.9). OxyContin declined −4.0% (−5.5,
2.4) each quarter on average following reformulation, which was
igniﬁcantly greater than the Other Opioid group (−1.5%, 95% CI:
2.3, −0.7).
The prescription adjusted OxyContin rate decreased −34.8%95% CI: −48.4, −17.7) after reformulation from baseline to 2015-
2 (Table 1, Fig. 5B). The decrease was statistically greater than the
ther Opioid group (10.8% 95% CI: −5.1, 29.5) as well as the other
ndividual opioids, except morphine. OxyContin declined −2.6%ependence 168 (2016) 219–229 223
(95% CI: −4.0 to −1.1) per quarter, which was signiﬁcantly greater
than the Other Opioid group (-0.3%, 95% CI: −1.1, 0.5).
The units dispensed adjusted OxyContin rate decreased −23.8%
(95% CI: −39.8, −3.6) following reformulation, which was statisti-
cally different than the Other Opioid group 9.0%, 95%CI (7.3, 28.3).
3.6. Route of administration
Of the 1863 OxyContin cases received from poison centers from
January, 2010 to June, 2015, 1511 reported the route of use: 1057
oral and 454 non-oral. Route was  not reported for the remainder.
The rate of OxyContin abuse using for the oral route decreased
from 0.0285 per 100,000 population before reformulation to 0.0082
in 2015-Q2, a 71.0% (95% CI: −76.9, −63.7) reduction (Fig. 6).
The non-oral route decreased from 0.0184 per 100,000 popula-
tion before reformulation to 0.0025 in 2015-Q2, an 86.7% (95% CI:
−91.9, −78.0) reduction, which was signiﬁcantly greater than the
oral route (p = 0.006).
3.7. Street price
A total of 3537 street price reports for OxyContin were sub-
mitted. The price of single-entity oxycodone, original formulation
OxyContin and reformulated OxyContin all decreased from 2011
through 2015. The geometric mean price of OxyContin original for-
mulation decreased from $1.40 to $0.61 from 2011 to 2015, a 57%
(95% CI: 37% to 70%, p < 0.001) reduction. The geometric mean price
of reformulated OxyContin decreased from $0.89 to $0.53 from
2011 to 2015, a 41% (95% CI: 19%, 57%, p = 0.001) reduction. The
difference in price for original and reformulated OxyContin was
36% in 2011 and 13% in 2015 (Fig. 7).
4. Discussion
The introduction of abuse deterrent formulations has created
controversy regarding their value in reducing abuse of opioid anal-
gesics. Concerns regarding abuse deterrent formulations involve 1)
the potential for overprescribing because prescribers may under-
estimate the abuse risk of an analgesic with abuse deterrent
properties, 2) dissemination of techniques to subvert an abuse
deterrent mechanism and thereby allow abuse to rebound or
increase, and 3) switching of abuse to other opioids or relying more
heavily on oral abuse.
Concerns about escalating prescribing of OxyContin are not sup-
ported by our results. After reformulation, the number of OxyContin
prescriptions dispensed decreased progressively over 5 years. This
change is notable because the prescription volume for OxyCon-
tin had increased greatly since its introduction in 1996. Other
investigators have documented a substantial decrease in Oxy-
Contin prescriptions following reformulation (Hwang et al., 2015;
Larochelle et al., 2015).
The sudden decrease in OxyContin prescriptions dispensed sug-
gests that there was a sudden decrease in demand. While there
were likely other factors involved, a substantial decrease in a short
period limits the potential inﬂuence of other factors and sug-
gests that abusers reduced their attempts to obtain OxyContin. For
most pharmaceuticals, the prescriber controls the supply of a drug,
but prescription opioids are unusual because abusers can stimu-
late prescription writing. A decrease in the number of attempts
to secure a prescription by feigning a painful condition (“doctor
shoppers”) could decrease the number of prescriptions dispensed,
particularly in the period immediately after reformulation. The sub-
sequent long gradual decrease in prescribing seems more likely to
be inﬂuenced by factors in addition to doctor shopping, like restric-
tions implemented by insurers and perceptions by prescribers. Each
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xtended release (ER) hydrocodone, IR and ER morphine, IR and ER hydromorphon
ime  indicated by shading was  excluded from statistical analysis. CI − 95% Conﬁden
f these reasons could potentially drive prescribers away from Oxy-
ontin and towards prescribing of other opioid analgesics.
In contrast to OxyContin, the number of prescriptions dis-
ensed for the Other Opioid Group increased from 2010 to 2012,
hen plateaued from 2012 to 2014, and ﬁnally decreased when
ydrocodone was reclassiﬁed as a Schedule 2 controlled substance.
ncreased prescribing of prescription opioid analgesics is a legiti-
ate concern, but prescription data do not indicate that OxyContin
as been affected.
We  found that abuse and diversion of OxyContin as measured
y 4 programs decreased promptly and progressively over 5 years.
n addition, the street price for the reformulated product was
uch lower than the original formulation. Other investigators have
eported substantial reductions in OxyContin abuse after reformu-
ation. (Buer et al., 2014; Butler et al., 2013; Coplan et al., 2013;
avens et al., 2014; Larochelle et al., 2015; Severtson et al., 2013;
essler et al., 2014), but included much shorter periods of evalu-
tion after reformulation. Similarly, introduction of reformulated
xyContin in Australia was followed by decreased prescribing,
buse, injection and snorting (Degenhardt et al., 2015). A dissenting
iew submitted to the FDA found that the endorsement of non-
edical use of OxyContin in the National Survey of Drug Use and
ealth (NSDUH) did not differ between periods (one year before
nd after its reformulation; Novak, 2013).However, this analysis
ccurred soon after reformulation. Given the time needed for ahe Other Opioid Group is comprised of immediate release (IR) oxycodone, IR and
nd ER tramadol, IR and ER oxymorphone, and IR and ER tapentadol. The period of
ervals. (A) Rate adjusted for population. (B) Rate adjusted for prescription volume.
reformulated product to permeate the market, it is likely that the
original formulation was  readily accessible for much of the analysis
period. Analysis of current data from NSDUH indicates trends simi-
lar to our results. After increasing from 2004 to 2010, endorsement
of past year nonmedical use of OxyContin decreased 23.7% from
2011 to 2014 (Fig. 8).
Our analytic models assumed a constant effect for other inter-
ventions that were enacted during the study period, such as
expansion of prescription drug monitoring plans (PDMPs), Risk
Evaluation and Mitigation Strategies (REMS), pill mill legislation,
and improved access to drug treatment, among many others.
Hence, there may  be an interaction between reformulation, preven-
tion initiatives and interventions, and prescribing practices. One
perspective to inform the extent of this limitation is to examine
demand for OxyContin. Our results suggest that the desirabil-
ity of OxyContin decreased as indicated by concurrent decreased
prescription volume, decreased diversion and reduction in street
price. The street price of the original formulation fell 57% from
2011 to 2015. Furthermore, the Drug Diversion program found a
85.6% reduction in OxyContin diversion by 2015-Q2, so the price
decreased while diversion also decreased, suggesting markedly
reduced demand for OxyContin.The decrease in price for the original formulation of OxyCon-
tin was unexpected since classic supply and demand theory would
indicate that a very desirable drug with decreased supply should
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nd  extended release (ER) hydrocodone, IR and ER morphine, IR and ER hydromorp
f  time indicated by shading was excluded from statistical analysis. CI − 95% Conﬁde
esult in a higher price. However, there are several factors that likely
ndermined the price of the original formulation. First, it is likely
hat buyers realized that the original formulation was no longer
roduced and that there are many counterfeit products posing as
he original formulation. Also important is the growing availability
nd affordability of potent heroin.
Overall, OxyContin demonstrated the greatest relative decrease
n rates of abuse and diversion of all opioid groups throughout
he study period. As importantly, the time course of change in
he various opioid groups was different. OxyContin prescriptions,
iversion, and abuse all decreased abruptly, within months or one
ear after its reformulation depending on the program. The initial
teep decrease was followed by a more gradual decrease. During the
nitial decrease, it is likely that there were no major confounders
cting to reduce diversion and abuse of OxyContin. There were
ndoubtedly a multitude of small interventions like drug take-back
ays and news stories in the popular press that may  have affected
erceptions of prescription opioid abuse in general. However, to
ur knowledge, no major interventions occurred in late 2010 or
arly 2011 that would be expected to selectively decrease Oxy-
ontin diversion and abuse. Therefore, we conclude that the initial
ecrease was largely caused by a decrease in abuse and diversion
aused by reformulation of OxyContin.
The possibility that these changes were caused by reformulation
s reinforced by the observed increase in prescriptions dispensed2015The Other Opioid Group is comprised of immediate release (IR) oxycodone, IR
 IR and ER tramadol, IR and ER oxymorphone, and IR and ER tapentadol. The period
tervals. (A) Rate adjusted for population. (B) Rate adjusted for prescription volume.
as well as an increase in abuse and diversion for the Other Opioid
group from 2010 to 2012. After increasing, the Other Opioid group
then plateaued and decreased through mid-2015. This observation
suggests that prescribing patterns and abuse behaviors switched
initially toward the other opioid analgesics, primarily immediate
release oxycodone, hydromorphone and morphine before other
factors reduced the abuse of those products as well. This interpre-
tation is supported by the fact that rates adjusted for population
showed the greatest increases, but rates adjusted for prescription
volume were less affected, indicating that abuse per unit of drug
did not increase substantially, just the amount of drug dispensed.
The route of abuse as represented by the Poison Center Program
indicates that both oral and non-oral routes of abuse decreased
although the decrease in non-oral abuse was  greater. This result
may  seem paradoxical as observers have predicted that ADFs
should affect primarily nasal insufﬂation or injection. (United States
Food and Drug Administration, 2015; Leece et al., 2015) The pro-
gression from swallowing to snorting or injection is often viewed
as unidirectional with snorting or injection displacing oral abuse.
However, research indicates most abusers endorse both oral and
non-oral use, perhaps depending on their desire and needs at the
time of abuse as well as the environment of abuse (Katz et al., 2011;
Surratt et al., 2011). Furthermore, most studies do not collect data
on chewing, which is a common form of tampering. In poison cen-
ters, chewing is classiﬁed as oral. Therefore, decreased abuse in a
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Fig. 5. Change in rate of abuse endorsement, Survey of Key Informant Patients, 2009–2015. The Other Opioid Group is comprised of immediate release (IR) oxycodone, IR
and  extended release (ER) hydrocodone, IR and ER morphine, IR and ER hydromorphone, IR and ER tramadol, IR and ER oxymorphone, and IR and ER tapentadol. The period
of  time indicated by shading was  excluded from statistical analysis. CI − 95% Conﬁdence intervals. (A) Rate adjusted for population. (B) Rate adjusted for prescription volume.
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n  mouth, and chewing then swallowing. Category of non-oral route includes injec
nalysis.on-oral route would be expected to reduce concomitant use by
wallowing intact or chewing and swallowing, which would then
educe the number of oral abuse events as well.rmulation. The category of oral route includes swallowing tablet whole, dissolving
r inhalation. The period of time indicated by shading was excluded from statisticalOur analysis has several limitations. Morphine extended release
has been proposed as an appropriate comparator for oxycodone
extended release because it comprises a large part of the extended
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Fig. 7. Reported street price trends of oxycodone products on StreetRx.com.
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Fig. 8. Trends of Endorsement for past year nonmedical use of OxyContin in
National Survey of Drug Use and Health.
The number of past year endorsements for each year are plotted by year:
2004–2014. The vertical line indicates introduction of reformulated OxyContin.
2013: http://archive.samhsa.gov/data/NSDUH/2013SummNatFindDetTables/
DetTabs/NSDUH-DetTabsSect1peTabs1to46-2013.htm#tab1.1a, page 120
2012: http://archive.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/
DetTabs/NSDUH-DetTabsSect1peTabs1to46-2012.htm#Tab1.1A
2011: http://archive.samhsa.gov/data/NSDUH/2011SummNatFindDetTables/
NSDUH-DetTabsPDFWHTML2011/2k11DetailedTabs/Web/HTML/NSDUH-
DetTabsSect1peTabs1to46-2011.htm#Tab1.1A
2010: http://archive.samhsa.gov/data/NSDUH/2k10ResultsTables/
NSDUHTables2010R/HTM/Sect1peTabs1to46.htm#Tab1.1A
2009: http://archive.samhsa.gov/data/NSDUH/2k10ResultsTables/
NSDUHTables2009R/HTM/Sect1peTabs1to46.htm#Tab1.1A
2008: http://archive.samhsa.gov/data/NSDUH/2k10ResultsTables/
NSDUHTables2008R/HTM/Sect1peTabs1to46.htm#Tab1.1A
2007: http://archive.samhsa.gov/data/NSDUH/2k10ResultsTables/
NSDUHTables2007R/HTM/Sect1peTabs1to46.htm#Tab1.1A
2006: http://archive.samhsa.gov/data/NSDUH/2k10ResultsTables/
NSDUHTables2006R/HTM/Sect1peTabs1to46.htm#Tab1.1A
2005: http://archive.samhsa.gov/data/NSDUH/2k5nsduh/tabs/Sect1peTabs1to66.
htm#Tab1.1A
2004: http://archive.samhsa.gov/data/NSDUH/2k4nsduh/2k4tabs/
Sect1peTabs1to66.htm#tab1.1a
Data were obtained from the detailed tables published by Substance Abuse andE = single entity. IR = immediate release formulations.
elease opioid market. We  chose a compound endpoint of the group
f Other Opioids because morphine alone is a poor choice for a
omparator. The primary concern is that abusers identify immedi-
te release oxycodone, hydromorphone, and oxymorphone, rather
han morphine, as the drugs they use when OxyContin is not avail-
ble (Cicero and Ellis, 2015). Also important is the fact that the
orphine market is highly inﬂuenced in recent years by increased
n low-abuse risk populations because it is increasingly required by
ealth plans to be used before OxyContin. Since OxyContin abusers
ave reported switching to a variety of prescription opioid anal-
esics, we concluded that the most defensible position is to include
ll of the opioids together and then to break out the major generic
ategories for investigators to interpret for themselves.
Another limitation of the poison center and street price data
s spontaneous reporting. Various factors may  inﬂuence the deci-
ion for someone to contact these programs. Data from the Poison
enter, Opioid Treatment, Survey of Key Informants’ Patients and
treetRx programs are based on self-reported information with all
he limitations inherent to that process such as misidentiﬁcation
y the abuser. The extent of this misidentiﬁcation is unknown, but
s the lowest for the Drug Diversion program because the inves-
igator often has the tablet for identiﬁcation. These biases are not
hought to vary substantially over time. Each program has been in
peration for many years and there were not changes in the pro-
rams that coincided with decreased rates of OxyContin diversion
r abuse. Furthermore, the trends from these programs have lasted
or 5 years, have substantial magnitude and are consistent with
ur data from treatment programs and with the medical literature.
evertheless, the potential for confounding is present.
Despite methods to circumvent the abuse deterrent mechanism,
buse and diversion of OxyContin decreased promptly following
he introduction of a crush- and solubility- resistant formulation
nd continued to decrease over the subsequent 5 years. Part of
he response may  be explained by a general decrease in abuse and
iversion of opioid analgesics in general. The temporal proﬁle of an
brupt decrease in prescription volume and rates of diversion and
buse as well as supporting evidence of decreased non-oral abuse
nd street price and similar results in the medical literature sup-
ort the conclusion that the reformulation of OxyContin decreased
ts abuse and diversion.
There are currently few products with FDA-approved label-
ng that includes statements about abuse deterrent properties. Of
hese, only OxyContin has a sufﬁcient number of dispensed pre-
criptions to measure it in postmarketing surveillance systems.
ssentially all data from several sources indicate it’s effectiveness
n reducing diversion and abuse of OxyContin itself. It may  have
n effect on the abuse of extended release opioid analgesics as a
roup since those products are also experiencing a decrease (Dart
t al., 2015). However, the effect on overall abuse of all opioid
nalgesics is unlikely to be measurable because extended releaseMental Health Services Administration for 2010–2014:
opioids represent a small part of the opioid market. In order to prop-
erly understand the impact of abuse deterrent opioids, most of the
opioid market needs to be comprised of ADF products.
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